Trilostane (CAS 13647-35-3) is a highly potent steroidogenesis inhibitor, with its core mechanism of action being the precise inhibition of 3β-hydroxysteroid dehydrogenase. It blocks the synthesis of steroid hormones such as glucocorticoids and mineralocorticoids in the adrenal cortex, thereby regulating abnormal hormone levels from the source.
Its high-purity chemical properties ensure the stability and reliability of its efficacy. Compared with similar drugs, it has the outstanding advantages of strong targeting and low side effects, which can effectively exert pharmacological effects while reducing interference with the normal physiological functions of the body.
This product is suitable for the clinical treatment of canine Cushing’s syndrome, and can also serve as a key experimental material for endocrine drug research and development, as well as steroid metabolism mechanism studies. For pet diagnosis and treatment institutions, veterinary drug R&D enterprises and scientific research institutes, this product combines clinical treatment practicality with scientific research exploration value. It can not only meet the treatment needs of clinical diseases, but also provide high-quality experimental sample support for research in related fields.
